Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study

医学 封锁 结直肠癌 新辅助治疗 打开标签 肿瘤科 癌症 内科学 受体 临床试验 乳腺癌
作者
Gong Chen,Ying Jin,Wen‐Long Guan,Rongxin Zhang,Weiwei Xiao,Peiqiang Cai,Min Liu,Junzhong Lin,Fulong Wang,Cong Li,Tingting Quan,Shaoyan Xi,Huizhong Zhang,Zhizhong Pan,Rui Wang,Rui‐Hua Xu
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:8 (5): 422-431 被引量:56
标识
DOI:10.1016/s2468-1253(22)00439-3
摘要

Summary

Background

The current standard treatment for locally advanced rectal cancer is neoadjuvant chemoradiotherapy followed by radical surgery, but this approach can lead to multiple complications. We aimed to investigate the clinical activity and safety of neoadjuvant therapy with sintilimab, a single-agent PD-1 antibody, in patients with mismatch-repair deficient locally advanced rectal cancer.

Methods

This open-label, single-arm, phase 2 study was done at the Sun Yat-sen University Cancer Center, Guangzhou, China. Patients aged 18–75 years with mismatch-repair deficient or microsatellite instability-high locally advanced rectal cancer were enrolled and received neoadjuvant sintilimab monotherapy (200 mg by intravenous infusion) every 21 days. After an initial four cycles of treatment, patients and clinicians could choose one of the following options: total mesorectal excision surgery, followed by four cycles of adjuvant sintilimab with or without CapeOX chemotherapy (capecitabine 1000 mg/m2, orally administered twice daily on days 1–14; oxaliplatin 130 mg/m2, intravenously administered on day 1 every 3 weeks), determined by clinicians; or another four cycles of sintilimab followed by radical surgery or observation (only for patients with a clinical complete response; also known as the watch and wait strategy). The primary endpoint was the complete response rate, which included both a pathological complete response after surgery and a clinical complete response after completion of sintilimab treatment. Clinical response was evaluated by digital rectal examination, MRI, and endoscopy. Response was assessed in all patients who received treatment at least until the first tumour response assessment, after the first two cycles of sintilimab. Safety was analysed in all patients who received at least one dose of treatment. This trial is closed to enrolment and is registered with ClinicalTrials.gov (NCT04304209).

Findings

Between Oct 19, 2019, and June 18, 2022, 17 patients were enrolled and received at least one dose of sintilimab. The median age was 50 years (IQR 35–59) and 11 (65%) of 17 patients were male. One patient was excluded from efficacy analyses because they were lost to follow-up after the first sintilimab cycle. Of the remaining 16 patients, six underwent surgery, of whom three had a pathological complete response. Nine other patients had a clinical complete response and chose the watch and wait strategy. One patient had a serious adverse event and discontinued treatment; this patient did not have a complete clinical response and refused to undergo surgery. A complete response was thus noted for 12 (75%; 95% CI 47–92) of 16 patients. One of the three patients who underwent surgery but did not have a pathological complete response showed an increase in tumour volume after the initial four cycles of sintilimab (at which point they underwent surgery); this patient was deemed to have primary resistance to immune checkpoint inhibitors. After a median follow-up of 17·2 (IQR 8·2–28·5) months, all patients were alive and none had disease recurrence. Only one (6%) patient had a grade 3–4 adverse event, which was deemed a serious adverse event (grade 3 encephalitis).

Interpretation

The preliminary results of this study suggest that anti-PD-1 monotherapy is effective and tolerable for patients with mismatch-repair deficient locally advanced rectal cancer and could potentially spare some patients from radical surgery. Longer treatment courses might be needed to achieve maximum effects in some patients. Longer follow-up is also needed to observe the duration of response.

Funding

The National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, Science and Technology Program of Guangzhou, and Innovent Biologics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
小二郎应助Kevin采纳,获得10
3秒前
4秒前
4秒前
gjww应助苛苛采纳,获得10
4秒前
6秒前
7秒前
YD发布了新的文献求助20
9秒前
信仰完成签到,获得积分10
9秒前
9秒前
壮观以山发布了新的文献求助10
10秒前
liruiyi完成签到,获得积分10
11秒前
吉祥财子发布了新的文献求助50
11秒前
wbbb发布了新的文献求助20
12秒前
PiggyBrother发布了新的文献求助30
13秒前
发发发完成签到,获得积分10
15秒前
15秒前
SciGPT应助复杂的如萱采纳,获得10
19秒前
20秒前
长情契应助夏青荷采纳,获得10
20秒前
20秒前
22秒前
Cassie发布了新的文献求助10
24秒前
25秒前
heng发布了新的文献求助10
26秒前
自然之水完成签到,获得积分10
26秒前
领导范儿应助酷酷妙梦采纳,获得10
26秒前
26秒前
我是老大应助Fn采纳,获得20
27秒前
小蘑菇应助wlz采纳,获得10
28秒前
乐观期待完成签到,获得积分10
31秒前
SciGPT应助喝杯水再走采纳,获得10
32秒前
32秒前
yixiao发布了新的文献求助10
35秒前
hilda完成签到,获得积分10
35秒前
35秒前
温柔惜筠应助weiquanfei采纳,获得10
36秒前
勤奋艳血完成签到,获得积分10
37秒前
39秒前
wxyllxx发布了新的文献求助10
40秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3136302
求助须知:如何正确求助?哪些是违规求助? 2787407
关于积分的说明 7781286
捐赠科研通 2443393
什么是DOI,文献DOI怎么找? 1299137
科研通“疑难数据库(出版商)”最低求助积分说明 625357
版权声明 600939